- Research
- Open access
- Published:
Interruptible demyelination in avian riboflavin deficient neuropathy
Cell & Bioscience volume 14, Article number: 52 (2024)
Abstract
Background and aims
The evolution of demyelination in individual internodes remains unclear although it has been noticed the paranodal demyelination precedes internodal demyelination in neuropathies with diverse aetiologies. For therapeutic purpose, it is fundamental to know whether the demyelinating procedure in affected internodes can be interrupted. This study aimed to delineate the development of demyelination in individual internodes in avian riboflavin deficient neuropathy.
Methods
Newborn broiler meat chickens were maintained either on a routine diet containing 5.0 mg/kg riboflavin, a riboflavin deficient diet containing 1.8 mg/kg riboflavin, or initially a riboflavin deficient diet for 11 days and then routine diet plus riboflavin repletion from day 12. Evolution of demyelination in individual internodes was analyzed by teased nerve fibre studies from day 11 to 21.
Results
In riboflavin deficient chickens, demyelination was the predominant feature: it was mainly confined to the paranodal region at day 11; extended into internodal region, but less than half of the internodal length in most affected internodes at day 16; involved more than half or whole internode at day 21. In the internode undergoing demyelination, myelin degeneration of varying degrees was noticed in the cytoplasm of the Schwann cell wrapping the internode. Two days after riboflavin repletion, co-existence of remyelination and active demyelination within individual internodes was noticed. Remyelination together with preserved short original internodes was the characteristic feature 4 and 9 days after riboflavin repletion.
Conclusion
Riboflavin repletion interrupts the progression from paranodal to internodal demyelination in riboflavin deficient chickens and promotes remyelination before complete internodal demyelination.
Introduction
Segmental demyelination, firstly described in lead neuropathy in guinea pig by Gombault in 1880, refers to myelin degeneration of a paranode (paranodal segmental demyelination) or an internode (internodal segmental demyelination) [1]. Early changes at the paranodal region have been found in demyelination of many types either primary, such as inflammatory [2, 3] and toxic [4,5,6] or secondary to axonal change [7]. It is believed that paranodal demyelination precedes internodal demyelination in both the peripheral nervous system (PNS) [8] and central nervous system (CNS) [9, 10]. However, the procedure from paranodal to complete internodal demyelination has not been previously described. For potential therapeutic purpose, it is fundamental to know whether the progression from paranodal to internodal demyelination is an irreversible process once initiated or whether the demyelinating procedure in affected internodes can be interrupted.
Riboflavin (a water-soluble vitamin, vitamin B2, VB2) and its derivatives are coenzymes for numerous oxidases and dehydrogenases in eukaryotic cells [11]. Riboflavin deficiency leads to impaired β-oxidation of fatty acids [12] and significant change in proteomic profiles [13]. New-born chickens fed with riboflavin-deficient (VB2−) diet develop a demyelinating peripheral neuropathy [6, 14,15,16,17]. Remyelination and spontaneous recovery after about 3 weeks may be due to endogenous microbial synthesis of riboflavin in the intestine (absent in newborn chicks) [18]. Previous studies in avian riboflavin deficient neuropathy found early changes at the paranodal region [15, 16], implying beginning of this pathogenic process. Here, by way of teased nerve fibre (TF) studies, we delineated the evolution of demyelination in affected internodes with the focus on interruption of this demyelinating procedure by VB2 repletion (VB2+).
Materials and methods
The avian riboflavin deficiency model of demyelinating peripheral neuropathy has previously been described [15]. In the current study, newborn broiler meat chickens (Cobb 500, Cobb-Vantress Inc, Arkansas, USA) were maintained ad libitum on (1) a conventional diet containing 5.0 mg/kg riboflavin, control groups; (2) a deficient diet containing 1.8 mg/kg riboflavin, VB2− groups; (3) initial riboflavin deficient diet for 11 days and then from post hatch day 12 (PH12d) conventional diet plus intraperitoneal injection of 0.5 ml Vitamin B Complex Injection containing 0.5 mg/ml VB2 (Ceva Animal Health, Australia), VB2−/+ groups. Five animals in each group were studied. Control and VB2− chickens were killed on PH11d, PH16d and PH21d, and VB2−/+ chickens on PH14d, PH16d and PH21d by transcardiac perfusion with 4% paraformaldehyde 0.1 M phosphate buffer (pH 7.4). Left sciatic and brachial nerves were processed according to a standard peripheral nerve biopsy protocol for light microscopy (LM) and electron microscopy (EM) [19]. Right sciatic and brachial nerves were prepared for sectional studies of resin teased nerve fibres (TFs) according to a published method [20]. In brief, after the perfusion, right sciatic and brachial nerves were further fixed in 4% paraformaldehyde/2.5% glutaraldehyde in 0.1 M phosphate buffer for 1.5 h and postfixed in 1% osmium tetroxide for 2 h. After washing in the cacodylate buffer, nerves were dehydrated in graded ethanol, softened in fresh epoxy resin for 3 days. Individual nerve fibres were isolated in fresh epoxy resin and mounted onto a carbon-coated slide. Fifty TFs from each nerve were prepared. Some fibres were further marked at specific sites using short TFs as “marker” fibres and left in an oven for resin polymerization. A small capsule (for routine electron microscopy resin embedding) filled with fresh resin was placed upside down onto the carbon-slide, covering the area that contained the teased fibres, and left in the oven for resin polymerization. The under surface of the slide was placed on top of a solid metal block, which was pre-cooled in liquid nitrogen. Due to the temperature difference, the resin block separated from the slide along the line of the carbon coat, with the fibres remaining on the surface of the resin block. Longitudinal sections of individual nerve fibres were collected from this resin block using an ultramicrotome. This resin block may also be trimmed around the fibres and placed in a capsule filled with fresh resin, keeping the teased fibres parallel to the long axis of the capsule, and the resin polymerized as above. The fibres were then transversely sectioned at specified sites to correlate with abnormalities seen on teased preparation.
Results
As reported previously, no neurological signs and pathological changes were found in control animals; VB2− chickens showed progressive weakness and paresis from PH8d until end of this study [15]. The paresis in VB2−/+ chickens became stable at PH16d (4 days after VB2 repletion), and gradually recovered thereafter. Routine pathological examination (Table 1) revealed predominant demyelination in all VB2− groups and predominant remyelination in VB2−/+ chickens at PH16d and PH21d. Endoneurial oedema, hypertrophic Schwann cells with lipid deposition, complex myelin foldings with varying stages of degeneration and myelin fragments in Schwann cell cytoplasm, as noticed in VB2− chickens [15], were also found in VB2−/+ chickens at less severity. But there were no obvious difference of hypertrophic fibroblasts and onion bulb formation [14] between VB2− and VB2−/+ chickens at the same time points. Macrophage-mediated myelin stripping, as described in both human and animal inflammatory demyelinating neuropathies [3, 21], was not found here. Sciatic and brachial nerves showed same pathological changes.
TF studies in VB2 − chickens
Fifty TFs were prepared from each animal. In control animals, at least 5 consecutive internodes in each fibre were examined. Pathological nerve fibres with similar length were examined. Demyelination was the predominant change in TF preparations from all VB2− groups. At PH11d (Fig. 1A), demyelination was mainly confined to the paranodal region, covering not more than 10 percent internodal length, paranodal demyelination. Normal internodes and demyelination were often noticed in the same fibres. At PH16d (Fig. 1B), paranodal demyelination was present in some internodes. In majority of affected internodes, demyelination involved both paranodal and adjoining internodal region, covering more than 10 percent of internodal length and the demyelinated segment not longer than that of neighbouring myelin sheath retained segment, partial internodal demyelination. In some affected internodes, demyelination involved whole internode or the demyelinated segment longer than that of neighbouring myelin retained segment, internodal demyelination. Demyelination of different types were often noticed in the same fibres. At PH21d (Fig. 1C), internodal demyelination was the major type. Quantitative analyses (Table 2) confirmed: the average percentage of paranodal demyelination decreased significantly with age, whereas the percentage of internodal demyelination increased significantly with age; the percentage of partial internodal demyelination increased significantly from P11d to P16d and then decreased significantly at P21d. These results suggest the evolution of demyelination in VB2− chickens: starting from paranodal region, progressing into internodal region, and finally involving whole internode.
Sectional studies were performed in 50 TFs with different types of demyelination (Fig. 1). “Naked” axon, axon without surrounding myelin sheath, was present in the demyelinated regions of various types. It was better demonstrated in longitudinal sections of TFs (Fig. 1A and B): active myelin degeneration in myelin retained segments, more severe close to the denuded site; and well-preserved myelin and Schwann cell nucleus in the middle. Myelin fragments was often noticed in the cytoplasm of the Schwann cell enwrapping the internode, which was better demonstrated in transverse sections of TFs (Fig. 1C). Macrophage stripping myelin, as reported in inflammatory demyelinating neuropathies, was not found here by electron microscopy in both transverse and longitudinal sections of TFs. The axon in the demyelinated sites were preserved but often attenuated. These findings further confirmed the evolution of demyelination, proceeding from paranodal gradually into internodal region, and suggest the “myelinating” Schwann cells play a pivotal in myelin degeneration and clearance.
Like previously reported, enveloping fibroblastic reaction [14] was noticed in all groups, but more prominent at PH16d and PH21d.
TF studies in VB2 −/+ chickens
At PH14d (2 days after riboflavin repletion), paranodal and partial internodal demyelination were the predominant change according to the surface appearances (Figs. 2 and 3A). But sectional studies revealed the following features in 14/20 examined such “demyelinating” fibres: (1) a Schwann cell nucleus in the “denuded” region, even a very short segment (50 µm), e.g., panels 2 and 3 right in Fig. 2 and panels 4 and 5 in Fig. 3A; (2) a few numbers of myelin lamellae around the axon with inner mesaxon connecting the axon and outer mesaxon connecting the Schwann cell basal membrane, indicating this Schwann cell was myelinating the axon, e.g., panel 4 in Fig. 2; (3) active myelin degeneration at the peripheries of myelin retained segments (here named original internodes), e.g. panel 3 right in Fig. 2 and panels 4 and 5 in panel 3A. These results are interpreted as co-existence of remyelination and active demyelination within affected internodes.
At PH16d and PH21d (4 and 9 days after riboflavin repletion), remyelination (thin myelin sheath) was present in majority of TFs. In these remyelinating fibres, the characteristic feature was the short original internodes (with thick myelin sheaths), especially at PH21d: they were usually irregular, the shortest less than half of the longest and even some remyelinating internodes (Fig. 3B); sometimes regular, similar to the length of adjacent remyelinating internodes (Fig. 3C). Sectional studies of 38 such fibres revealed: (1) new nodes of Ranvier, which were hardly visible from the surface appearance especially at PH16d (Fig. 3B); (2) active myelin degeneration at the peripheries of original internodes at PH16d (Fig. 3B), but much less in frequency and severity at PH21d (Fig. 3C); (3) myelin debris in the cytoplasm of myelinating Schwann cell encompassing the original (e.g., panels 4 and 5 middle in Fig. 3B and panel 3 in Fig. 3C) and sometimes remyelinating internodes (e.g., panel 3 in Fig. 3C). These findings are interpreted as: the progression of demyelination within individual internodes was interrupted, at least alleviated; both the original myelinating Schwann cell and remyelinating Schwann cell involve in myelin clearance.
Enveloping fibroblasts as seen in VB2− animals were also present in VB2−/+ animals (Figs. 2 and 3).
Discussion
Demyelination in VB2− chickens proceeds from paranodal to central internodal region and is driven by Schwann cell
In the current study, morphometric analyses revealed significant changes from predominant paranodal demyelination at PH11d, to predominant partial internodal demyelination at PH16d, and then predominant internodal demyelination at PH21d. Sectional studies of TFs further demonstrated incipient myelin degeneration at paranodal and later at internodal region. These findings confirmed that, as expected, demyelination in VB2− chickens proceeds from paranodal to internodal region until the full length of the internode is affected.
It is generally accepted that macrophage-mediated myelin degeneration and clearance play the pivotal role in the pathogenic mechanism in demyelinating neuropathies with various aetiologies. However, the concept of macrophage-mediated demyelination ignores morphological facts: myelin debris is more commonly found in Schwann cells than macrophages. Macrophage-mediated myelin stripping was not found in the current and previous studies by electron microscopy and immunohistochemistry. In contrast, varying stages of degenerated myelin fragments were found in the cytoplasm of hypertrophic Schwann cells [14,15,16,17], consistent with the myelin phagocytosis and clearance function of Schwann cell [22, 23]. Sectional studies of TFs here proved that the Schwann cell expressing such myelinolytic activity was the same Schwann cell enwrapping the internode, indicating that the original myelinating Schwann cell plays a critical role in initiating and promoting demyelination within the same internode. Such Schwann cell is named demyelinating Schwann cell [24]. The longitudinal extension of myelin degeneration and clearance from paranodal to internodal region by demyelinating Schwann cells is named Demyelination Driven by Demyelinating Schwann Cell (DDDSC), which is thought the common pathway of demyelination in immune-independent and some inflammatory demyelinating neuropathies [24, 25].
Interruptible demyelination and remyelination in VB2−/+ chickens
Paranodal origin of demyelination has been recognized in neuropathies with diverse aetiologies in both PNS and CNS [8,9,10]. It is commonly accepted: two or more Schwann cells remyelinate one completely demyelinated internode, resulting in short remyelinated internodes. It remains unclear: (1) whether remyelination could occur before one internode is completely demyelinated? (2) whether the demyelinating process within affected internodes could be stopped? Although there has been no previous study specifying the possibility to interrupt the evolution from paranodal to internodal demyelination, it is believed that whenever initiated, DDDSC will progress unidirectionally toward complete removal of intracellular myelin sheath debris before remyelination happens. This process is so-called irreversible demyelination [24]. But in the notion of irreversible demyelination [24], two facts are overlooked, rapid progression of the disease and continuous, even irreversible, effect of the pathogen. As the progression from paranodal to complete internodal demyelination takes a few (5–10) days in the current avian model, it provides a time window to interfere with this procedure. Importantly, the pathogenic factor, VB2−, is readily rectified by VB2+. VB2+ was applied from PH12d as myelin degeneration in most affected internodes was limited to the paranodal and adjoining regions with preservation of central internodal myelin segments at this time. Co-existence of remyelination and active demyelination within individual internodes in VB2−/+PH14d chickens indicates occurrence of remyelination before complete internodal demyelination. Presence of short original internodes in remyelinating fibres, especially at PH21d, suggests the demyelinating procedure in affected internodes be interrupted. This type of demyelination and remyelination in avian riboflavin deficiency is here named as interruptible demyelination driven by Schwann cell (IDDSC). Whether IDDSC applies to avian riboflavin deficiency only? The morphological features, myelin debris in Schwann cell cytoplasm, intercalated internode and so called “hypomyelination” noticed by conventional pathological examinations [1, 26, 27], suggest that IDDSC apply to demyelinating neuropathies with diverse aetiologies. In clinical practice, symptoms in some patients with demyelinating neuropathies improve soon after treatment. It may attribute to the interruptible process of demyelination. Studies in human samples, especially sectional studies of TFs, will test this speculation.
The current study provides morphological evidence. Molecular mechanisms for interruptible demyelination remain further studies. Because of the specific feature of myelinated fibres, long and segmental, it is proposed that investigation of dynamic molecular expressions, including related Schwann cell phenotypes, along a decent length of same fibres, such as multiple consecutive internodes, will be an important next step. It is anticipated that novel therapies to demyelinating neuropathies with diverse aetiologies may be developed accordingly.
In conclusion, demyelination in avian VB2− neuropathy proceeds from paranodal gradually to internode region; the Schwann cell, originally myelinating the internode, plays a pivotal role in this demyelinating procedure, myelin degeneration and clearance; VB2+ interrupts the demyelinating procedure in affected internodes and promotes remyelination before complete internodal demyelination.
Availability of data and materials
The data and materials are available.
References
Dyck PJ, Dyck PJB, Engelstad J, et al. Pathologic alterations of nerve. In: Dyck PJ, Thomas PK, Griffin J, et al., editors. Peripheral neuropathy. 4th ed. Philadelphia, PA: Elsevier; 2005. p. 733–829.
Koike H, Kadoya M, Kaida KI, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry. 2017;88:465–73. https://doi.org/10.1136/jnnp-2016-314895.
Koike H, Katsuno M. Macrophages and autoantibodies in demyelinating diseases. Cells. 2021;10:844. https://doi.org/10.3390/cells10040844.
Allt G, Cavanagh JB. Ultrastructural changes in the region of the node of Ranvier in the rat caused by diphtheria toxin. Brain. 1969;92:459–68. https://doi.org/10.1093/brain/92.2.459.
Uncini A, England JD, Rhee EK, et al. Tellurium-induced demyelination: an electrophysiological and morphological study. Muscle Nerve. 1988;11:871–9. https://doi.org/10.1002/mus.880110812.
Weller RO, Nester B. Early changes at the node of Ranvier in segmental demyelination. Histochemical and electron microscopic observations. Brain. 1972;95:665–74. https://doi.org/10.1093/brain/95.4.665.
Dyck PJ, Lais AC, Karnes JL, et al. Permanent axotomy, a model of axonal atrophy and secondary segmental demyelination and remyelination. Ann Neurol. 1981;9:575–83. https://doi.org/10.1002/ana.410090611.
Bilbao JM, Schmidt RE. Biopsy Diagnosis of Peripheral Neuropathy. 2nd ed. Cham: Springer; 2015. p. 85–110. https://doi.org/10.1007/978-3-319-07311-8.
Fu Y, Frederick TJ, Huff TB, et al. Paranodal myelin retraction in relapsing experimental autoimmune encephalomyelitis visualized by coherent anti-Stokes Raman scattering microscopy. J Biomed Opt. 2011;16: 106006. https://doi.org/10.1117/1.3638180.
Stojic A, Bojcevski J, Williams SK, Diem R, Fairless R. Early nodal and paranodal disruption in autoimmune optic neuritis. J Neuropathol Exp Neurol. 2018;77:361–73. https://doi.org/10.1093/jnen/nly011.
Rivlin RS. Riboflavin. In: Bowman BA, Russell RM, editors. Present knowledge in nutrition. 8th ed. Washington DC: ILSI Press; 2001. p. 191–8.
Ross NS, Hansen TP. Riboflavin deficiency is associated with selective preservation of critical flavoenzyme-dependent metabolic pathways. BioFactors. 1992;3(3):185–90.
Xin Z, Pu L, Gao W, Wang Y, Wei J, Shi T, Yao Z, Guo C. Riboflavin deficiency induces a significant change in proteomic profiles in HepG2 cells. Sci Rep. 2017;7:45861. https://doi.org/10.1038/srep45861.
Cai Z, Blumbergs PC, Finnie JW, et al. Novel fibroblastic onion bulbs in a demyelinating avian peripheral neuropathy produced by riboflavin deficiency. Acta Neuropathol. 2007;114:187–94. https://doi.org/10.1007/s00401-007-0215-8.
Cai Z, Finnie JW, Blumbergs PC, et al. Early paranodal myelin swellings (tomacula) in an avian riboflavin deficiency model of demyelinating neuropathy. Exp Neurol Exp Neurol. 2006;198:65–71. https://doi.org/10.1016/j.expneurol.2005.10.028.
Johnson WD, Storts RW. Peripheral neuropathy associated with dietary riboflavin deficiency in the chicken. I Light microscopic study. Vet Pathol. 1988;25:9–16. https://doi.org/10.1177/030098588802500102.
Jortner BS, Cherry J, Lidsky TI, et al. Peripheral neuropathy of dietary riboflavin deficiency in chickens. J Neuropathol Exp Neurol. 1987;46:544–55. https://doi.org/10.1097/00005072-198709000-00004.
Summers BA, Cummings JF, de Lahunta A. Veterinary neuropathology. St Louis: Mosby; 1995. p. 463–4.
Cash K, Blumbergs PC. Neuromuscular tissue. In: Woods AE, Ellis RC, editors. Laboratory histopathology: a complete reference, vol. 2. Edinburgh: Churchill Livingstone; 1995. p. 7.3.1-7.3.25.
Cai Z, Cash K, Swift J, et al. A novel method for correlating internal and external structure of individual myelinated nerve fibres. J Neurosci Methods. 2001;105:39–43. https://doi.org/10.1016/S0165-0270(00)00363-0.
Bensfield AC, Evans J, Pesayco JP, et al. Recurrent demyelination and remyelination in 37 young Bengal cats with polyneuropathy. J Vet Intern Med. 2011;25:882–9. https://doi.org/10.1111/j.1939-1676.2011.0740.x.
Balakrishnan A, Belfiore L, Chu TH, et al. Insights into the role and potential of Schwann cells for peripheral nerve repair from studies of development and injury. Front Mol Neurosci. 2021;13: 608442. https://doi.org/10.3389/fnmol.2020.608442.
Jessen KR, Mirsky R. The success and failure of the Schwann cell response to nerve injury. Front Cell Neurosci. 2019;13:33. https://doi.org/10.3389/fncel.2019.00033.
Park HT, Kim JK, Tricaud N. The conceptual introduction of the “demyelinating Schwann cell” in peripheral demyelinating neuropathies. Glia. 2019;67:571–81. https://doi.org/10.1002/glia.23509.
Park HT, Kim YH, Lee KE, et al. Behind the pathology of macrophage-associated demyelination in inflammatory neuropathies: demyelinating Schwann cells. Cell Mol Life Sci. 2020;77:2497–506. https://doi.org/10.1007/s00018-019-03431-8.
Kalichman MW, Chalk CH, Mizisin AP. Classification of teased nerve fibers for multicenter clinical trials. J Peripher Nerv Syst. 1999;4(3–4):233–44.
Sima AAF, Blaivas M. Peripheral neuropathies. In: Garcia JH, Budka H, McKeever PE, Sarnat HB, Sima AAF, editors. Neuropathology: the diagnostic approach. Mosby; 1997. p. 765–809.
Acknowledgements
The author thanks for long supports and valuable opinions for this manuscript from professors Peter C Blumbergs and John C Finnie and Mr Jim Manavis. Thanks to Inghams Enterprises, Adelaide, for the support of this study.
Funding
This research was initially supported by the Department funding. Because of the time-consuming nature of the specific technique, which is essential for this study, the funding was run out before the research is completed. Currently there is no public funding for it.
Author information
Authors and Affiliations
Contributions
The sole author contribute fully to this manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This experimental protocol was approved by the Animal Ethics Committee of the Institute of Medical and Veterinary Science (now named SA Pathology), Adelaide and conformed to the Australian Code of Practice for the Care and Use of Animals for Scientific Purpose.
Consent for publication
The author and the affiliated organizations give full consent for publication of this manuscript.
Competing interests
The author does not have competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Cai, Z. Interruptible demyelination in avian riboflavin deficient neuropathy. Cell Biosci 14, 52 (2024). https://doi.org/10.1186/s13578-024-01233-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13578-024-01233-5